VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

By WebmasterSeptember 4, 2019November 1st, 2024No Comments

VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

Previous PostBerwyn biopharma firm files for IPO
Next PostVenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections